KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

West Pharmaceutical Services (WST) Debt to Equity (2016 - 2026)

West Pharmaceutical Services has reported Debt to Equity over the past 18 years, most recently at $0.07 for Q1 2026.

  • Quarterly Debt to Equity fell 10.19% to $0.07 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $0.07 through Mar 2026, down 10.19% year-over-year, with the annual reading at $0.06 for FY2025, 15.46% down from the prior year.
  • Debt to Equity was $0.07 for Q1 2026 at West Pharmaceutical Services, up from $0.06 in the prior quarter.
  • Over five years, Debt to Equity peaked at $0.09 in Q1 2022 and troughed at $0.03 in Q4 2023.
  • The 5-year median for Debt to Equity is $0.07 (2024), against an average of $0.07.
  • Biggest five-year swings in Debt to Equity: crashed 67.18% in 2023 and later soared 198.91% in 2024.
  • Tracing WST's Debt to Equity over 5 years: stood at $0.08 in 2022, then crashed by 67.18% to $0.03 in 2023, then skyrocketed by 198.91% to $0.08 in 2024, then dropped by 15.46% to $0.06 in 2025, then rose by 6.21% to $0.07 in 2026.
  • According to Business Quant data, Debt to Equity over the past three periods came in at $0.07, $0.06, and $0.07 for Q1 2026, Q4 2025, and Q3 2025 respectively.